The 36-month PFS and OS of patients with or without POD24; subgroup analysis of the ELARA trial presented at the American Society of Hematology meeting 2023⁸ (with permission). CI, confidence interval; NE, not estimated; OS, overall survival; PFS, progression-free survival; POD24, progression of disease within 2 years of frontline systemic therapy.